Ozempic and Wegovy hit $21B in sales for Novo Nordisk in 2024. Everyone's circling 2031 for generic entry, but the patent data tells a different story. We mapped the full GLP-1 patent landscape using PatSeer, and here's what stands out: filings surged 62% post-2019, protection layers run deeper than standard expiry forecasts suggest, and certain major markets show openings years earlier than expected. For generic manufacturers and IP strategists, this timing gap is the entire strategy.
Read the complete analysis. https://bit.ly/4dec8tx
#patseer #patents #patentlandscape #PatentPortfolio #aipatentsearch #Patentanalysis #PatentInsights #PatentDatabase #PatentAnalytics #GLP1 #NovoNordisk
Comments